New Guidelines Advocate for Statin Use Among HIV-Positive Adults at Risk for Heart Disease

In a significant development for the healthcare of individuals living with HIV, a panel formed by the U.S. Department of Health and Human Services has recommended the use of statins for adults who are at risk of cardiovascular disease. This collaborative effort involved esteemed organizations such as the American College of Cardiology, the American Heart Association, and the HIV Medicine Association.

The recommendations stem from findings derived from the REPRIEVE (Randomized Trial to Prevent Vascular Events in HIV) study, which highlighted the increased susceptibility of people with HIV (PWH) to various age-related health conditions, particularly atherosclerotic cardiovascular disease (ASCVD). This global Phase III trial focused on the efficacy of pitavastatin in preventing ASCVD among participants aged 40 to 75 with low to moderate risk profiles based on projected 10-year risk assessments.

Results indicated that pitavastatin led to a 36% reduction in major adverse cardiovascular events (MACE) compared to the placebo group. These compelling results prompted the panel to advocate for moderate-intensity statin therapy as a primary preventive measure for PWH aged 40 to 75 who exhibit low to intermediate 10-year ASCVD risk.

Furthermore, the panel strongly advises initiating statin therapy for individuals with a 10-year ASCVD risk score of 5% or greater. In cases where the risk score is under 5%, while the panel supports the use of statin therapy, it emphasizes the need for thorough patient-clinician discussions to take into account HIV-related factors that may heighten ASCVD risk.

For those younger than 40 years living with HIV, the decision to commence statin therapy should be personalized, factoring in individual risk profiles and family medical histories. The recommendations specify the use of moderate-intensity statins, including options such as pitavastatin (4 mg daily), atorvastatin (20 mg daily), or rosuvastatin (10 mg daily).

The authors of the guidelines have noted that further research is essential to gain a deeper understanding of the absolute risk for ASCVD and other cardiovascular disease manifestations in the HIV-positive population.

For additional insights, the full recommendations are detailed in the Annals of Internal Medicine.